Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
WVE - Wave Life Sciences Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.00
DETAILS
HIGH:
$18.00
LOW:
$12.00
MEDIAN:
$13.00
CONSENSUS:
$14.00
UPSIDE:
171.32%
Stock News
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in August.
WAVE Life Sciences Q2 Earnings Call Highlights
WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026.
Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in MASH, type 2 diabetes, and other cardiometabolic diseases
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company's second quarter 2026 financial results and provide business updates.
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the “Singapore Court”).
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in June.
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Price Targets
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
$13.00
(was $5.51)
UBS
Wave Life Sciences price target lowered to $12 from $15 at Wedbush
$12.00
(was $5.48)
Wedbush
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
$13.00
(was $5.66)
New Street
Wave Life Sciences price target raised to $14 from $13 at Wells Fargo
$14.00
(was $6.14)
Wells Fargo
Wave Life Sciences price target lowered to $13 from $18 at H.C. Wainwright
$13.00
(was $6.40)
H.C. Wainwright
Wave Life Sciences assumed with a Buy at Truist
$15.00
(was $7.52)
Truist Financial
Wave Life Sciences price target lowered to $18 from $30 at H.C. Wainwright
$18.00
(was $7.26)
Andrew Fein
·
H.C. Wainwright
Wave Life Sciences price target lowered to $13 from $27 at Wells Fargo
$13.00
(was $6.37)
Wells Fargo
Wave Life Sciences price target lowered to $18 from $28 at Jefferies
$18.00
(was $6.20)
Jefferies
Wave Life Sciences price target lowered to $27 from $29 at Wells Fargo
$27.00
(was $13.27)
Wells Fargo
Wave Life Sciences price target raised to $43 from $40 at Canaccord
$43.00
(was $13.43)
Canaccord Genuity
Raymond James: 'WVE regains full economic rights to WVE-006 from GSK'
$26.00
(was $13.43)
Michael Freeman
·
Raymond James
Wave Life Sciences price target raised to $30 from $22 at H.C. Wainwright
$30.00
(was $16.57)
Andrew Fein
·
H.C. Wainwright
Wave Life Sciences price target raised to $32 from $24 at Oppenheimer
$32.00
(was $16.11)
UBS
WAVE Life Sciences (WVE) PT Raised to $32 at Oppenheimer
$32.00
(was $16.98)
Cheng Li
·
Oppenheimer
Wave Life Sciences price target raised to $50 from $36 at Truist
$50.00
(was $16.61)
Truist Financial
Wedbush raises price target on Wave Life Sciences, adds to Best Ideas List
$33.00
(was $16.74)
Yun Zhong
·
Wedbush
Wave Life Sciences price target raised to $34 from $12 at Cantor Fitzgerald
$34.00
(was $19.27)
Steve Seedhouse
·
Cantor Fitzgerald
Wave Life Sciences price target raised to $29 from $16 at Wells Fargo
$29.00
(was $18.52)
Wells Fargo
Wave Life Sciences price target raised to $30 from $16 at Citi
$30.00
(was $18.52)
UBS